In preclinical and clinical trials, Cedars-Sinai investigators develop novel, minimally invasive techniques — including hybrid approaches and imaging modalities — for improving outcomes and minimizing cumulative trauma to congenital heart patients.
In preclinical research, investigators study the use of new transcatheter valve implantations as well as technology and therapies that translate into clinical methods for the treatment of congenital heart disease.
- Principal investigators: Evan Zahn, MD
Cedars-Sinai researchers develop and implement catheterization and cardiovascular surgical intervention procedures in clinical trials to treat complex congenital problems. Researchers currently participate in the following clinical research projects:
- Fontan Udenafil Exercise Longitudinal (FUEL) Trial and the FUEL Open-Label Extension Trial: These trials are designed to determine the effect of udenafil, a novel PDE5 inhibitor, on exercise performance in the Fontan population over a six-month period, and to study the longer-term safety of udenafil over an additional 12 months. While exercise is the primary outcome, we will also evaluate the effect of udenafil on echo measures of ventricular function, serum biomarkers, endothelial function, and measures of quality of life. This is a Pediatric Heart Network, multicenter trial sponsored by the National Heart, Lung, and Blood Institute.
- Principal investigator: Ruchira Garg, MD
- HOPE-Duchenne (Halt cardiOmyopathy ProgrEssion in Duchenne Muscular Dystrophy): A randomized, open-label study of the safety and efficacy of multivessel, intracoronary delivery of allogeneic cardiosphere-derived cells in patients with cardiomyopathy secondary to Duchenne muscular dystrophy.
- Principal investigator: Ronald G. Victor, MD
Cedars-Sinai's congenital heart disease research is multidisciplinary, including adult and pediatric cardiologists and cardiothoracic surgeons.